Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA). BIDMC scientists received a total of 69 grants across all medical-center departments, including surgery, neurology, pathology and a wide swath of divisions within [...]

Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that [...]

Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
The first paper, from Dr. Pier Paolo Pandolfi (BIDMC and Harvard Medical School) and colleagues, demonstrates that the Ras-like small GTPase, Rheb, is directly involved in prostate tumorigenesis.